[Outcome of adjuvant mifurol chemotherapy in patients with resected colonic carcinoma].
The effectiveness of Mifurol as an adjuvant chemotherapy in colonic cancer patients has been assessed on the basis of long-term survival at various institutions. In the curative resection cases, the outcome of administrations of MMC (0.2 mg/kg x 2) + Mifurol (6-12 mg/kg/day) (group A and MMC (0.2 mg/kg x 2)+ Tegafur (12 mg/kg/day) (group B) was compared. There was no difference in the background factors or in the total amount of the alpha rugs administrated in these two groups. The five-year survival by Kaplan-Meirer's method were 56.1% and 36.1% for group A and B, respectively, the difference being particularly remarkable in Dukes C cases.